Longeveron Inc. Stock price

Equities

LGVN

US54303L2034

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
3.25 USD +4.50% Intraday chart for Longeveron Inc. -16.67% -76.10%
Sales 2024 * - Sales 2025 * 66.67K Capitalization 8.17M
Net income 2024 * -22M Net income 2025 * -21M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 123 x
P/E ratio 2024 *
-0.46 x
P/E ratio 2025 *
-0.59 x
Employees 24
Yield 2024 *
-
Yield 2025 *
-
Free-Float 36.25%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.50%
1 week-16.67%
Current month-39.14%
1 month-40.30%
3 months-76.62%
6 months-85.75%
Current year-76.10%
More quotes
1 week
2.92
Extreme 2.92
4.30
1 month
2.92
Extreme 2.92
5.52
Current year
2.92
Extreme 2.92
14.30
1 year
2.92
Extreme 2.92
44.00
3 years
2.92
Extreme 2.92
450.00
5 years
2.92
Extreme 2.92
450.00
10 years
2.92
Extreme 2.92
450.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 23-02-28
Founder 61 14-10-08
Director of Finance/CFO 64 23-07-30
Members of the board TitleAgeSince
Founder 61 14-10-08
Director/Board Member 77 23-06-08
Director/Board Member 56 21-02-11
More insiders
Date Price Change Volume
24-03-28 3.25 +4.50% 154,226
24-03-27 3.11 -9.51% 124,192
24-03-26 3.437 -14.61% 62,704
24-03-25 4.025 +5.37% 30,534
24-03-22 3.82 -2.05% 12,046

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Longeveron Inc. is a clinical-stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The Company is primarily focused on three pipeline indications, which include Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty. Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The Company has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
3.25 USD
Average target price
72.67 USD
Spread / Average Target
+2,135.90%
Consensus
  1. Stock
  2. Equities
  3. Stock Longeveron Inc. - Nasdaq